HK Stock Market Move | ASIAINFO TECH (01675) surges more than 5% during trading hours, with the company deeply involved in the Alibaba Cloud ecosystem. Institutions are optimistic about its potential growth opportunities.
AsiaInfo Technology (01675) surged more than 5% intra-day, rising 4.65% to HK$8.77 as of the time of publication, with a turnover of HK$40.47 million.
ASIAINFO TECH (01675) rose more than 5% during the trading session and, as of the time of writing, was up 4.65% at HKD 8.77 with a trading volume of HKD 40.4796 million.
According to media reports, Alibaba is preparing to revamp its flagship AI application to make it more like ChatGPT. It is reported that Alibaba has secretly launched the "Qianwen" project, creating a personal AI assistant app named Qianwen APP based on the Qwen model, in direct competition with ChatGPT and entering the top global AI application competition. Alibaba's core management sees this as the "future battle of the AI era" and hopes to win the competition with the advantage of Qwen's open-source technology after announcing a 380 billion yuan investment in AI infrastructure earlier this year, this is another important move in Alibaba's AI strategy.
Earlier, during the "2025 Alibaba Cloud Intelligence Summit," ASIAINFO TECH signed a cooperation agreement with Alibaba Cloud, officially becoming the "ability center" of Alibaba Cloud. The two sides will strengthen joint product development, service cooperation, and market development in various aspects such as Tongyi Qianwen Big Model, AI Integrated Machine, and AI Big Model Security. CMSC believes that ASIAINFO TECH's deep involvement in the Alibaba Cloud ecosystem is expected to benefit from Alibaba Cloud's strong computing power support and ecosystem resources, significantly enhancing competitiveness in AI project delivery efficiency, model application depth, and market expansion capabilities, creating more potential growth opportunities.
Related Articles

Jiangsu Hengrui Pharmaceuticals (600276.SH) has obtained the notification letter of approval for clinical trials of Rivaroxaban tablets.

CANSINOBIO(06185): TB vaccine for inhalation initiated Phase I clinical trials in Indonesia and completed the enrollment of the first subject.

VTECH HOLDINGS (00303) will distribute an interim dividend of $0.17 per share on December 19th.
Jiangsu Hengrui Pharmaceuticals (600276.SH) has obtained the notification letter of approval for clinical trials of Rivaroxaban tablets.

CANSINOBIO(06185): TB vaccine for inhalation initiated Phase I clinical trials in Indonesia and completed the enrollment of the first subject.

VTECH HOLDINGS (00303) will distribute an interim dividend of $0.17 per share on December 19th.

RECOMMEND

Younger consumers are dining out less at Chipotle and Cava while still buying Coach handbags
10/11/2025

Target’s deteriorating in-store experience risks recovery — retailer bets on a refined fulfillment model to fix it
10/11/2025

China suspends approval ban on exports of certain metals used in chip and electronics manufacturing to the U.S.
10/11/2025


